The patenting of human genes in Australia remains under court review. As reported in the blog Patentology, an appeal of the Australian decision, Cancer Voices et al. v. Myriad Genetics Inc. et al., was filed on March 4, 2013 to a Full Bench of the Federal Court of Australia by the law firm of Maurice Blackburn on behalf of cancer survivor Yvonne D’Arcy. As reported in my February 19, 2013 post, the lower court upheld claims to isolated polynucleotides comprising all, or a portion of the BRCA1 locus or of a mutated BRCA1 locus. The polynucleotides can be RNA, DNA, cDNA and synthetic forms.
Related Insights
July 2, 2025
Energy Current
Has SCOTUS Pre-decided Whether the NRC Can License Private Off-Site High-Level Nuclear Waste Storage Facilities?
On June 18, 2025, the U.S. Supreme Court, in NRC v. Texas, issued an opinion holding that the State of Texas did not have standing to…
July 2, 2025
Innovative Technology Insights
AI-Powered Text Messaging by Digital Health Companies: Supreme Court Raises the Stakes
Digital health companies increasingly rely on AI-powered messaging platforms, chatbots, and virtual assistants to engage patients through…
July 2, 2025
Health Care Law Today
AI-Powered Text Messaging by Digital Health Companies: Supreme Court Raises the Stakes
Digital health companies increasingly rely on AI-powered messaging platforms, chatbots, and virtual assistants to engage patients through…